SARS-CoV-2 vaccination willingness and predictors in patients with chronic inflammatory rheumatic diseases (CIRD) and without CIRD

被引:2
|
作者
Roman, Iulia [1 ,2 ]
Andreica, Ioana [1 ,2 ]
Baraliakos, Xenofon [1 ,2 ]
Redeker, Imke [1 ,2 ]
Kiltz, Uta [1 ,2 ]
Braun, Juergen [1 ,2 ]
机构
[1] Rheumazentrum Ruhrgebiet, Claudiusstr 45, D-44649 Herne, Germany
[2] Ruhr Univ Bochum, Bochum, Germany
关键词
COVID-19; inflammatory rheumatic diseases; predictors; SARS-CoV-2; vaccination willingness; COVID-19; INFECTIONS; ARTHRITIS;
D O I
10.1177/1759720X221093760
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recent surveys in chronic inflammatory rheumatic diseases (CIRD) showed a high degree of vaccine hesitancy. Current knowledge about patients' attitudes toward vaccination against SARS-CoV-2 is limited. Objectives: To assess the willingness of CIRD patients to be vaccinated against SARS-CoV-2 and to identify the influencing factors compared with non-CIRD patients. Methods: In this cross-sectional study, two cohorts of consecutive patients with and without CIRD were recruited in parallel when presenting to our tertiary hospital and asked to answer questions of a structured interview to assess vaccination willingness to SARS-CoV-2 their experience with SARS-CoV-2 and their personal history of infections and vaccinations. Vaccination willingness was assessed using a numerical rating scale (0: fully disagree; 10: fully agree). Arbitrarily defined cut-offs were used to define definite (score >= 7) and probable willingness (score of 5 or 6) to be vaccinated. Factors associated with willingness were assessed using Kendall's tau-b correlation measure and linear regression analysis. Results: A total of 514 CIRD and 100 non-CIRD patients, mean age of 54.7 +/- 12.8 and 55.6 +/- 9.8 years, respectively, were included. Definite and probable willingness to be vaccinated against SARS-CoV-2 was declared by 79.6% and 90.7% versus 76.0% and 85.0% of CIRD and non-CIRD patients, respectively. Only 60% of CIRD patients believed that the vaccines against SARS-CoV-2 were safe, and 42% indicated to be afraid of side effects. Vaccination willingness was significantly correlated with being in a risk group for COVID-19 (tau-b = -0.149), hypertension (tau-b = 0.14), and information about disease prevention (tau-b = 0.19), while a history of infections or immunosuppressive therapy was not. Vaccination willingness was significantly associated with higher education (b = 0.65) and age (b = 0.06). Conclusion: This survey highlights several predictors of relevance for the vaccination willingness of patients with CIRD and controls including appropriate information about its relevance. The good news, however, is that the vast majority of CIRD patients indicated their willingness to be vaccinated. However, there was some uncertainty regarding the safety and efficacy of the vaccines. Since the major influencing factors were education and information about SARS-CoV-2 Vaccine and COVID-19 Disease, patient education should be improved soon.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases
    Lawson-Tovey, Saskia
    Hyrich, Kimme L.
    Gossec, Laure
    Strangfeld, Anja
    Carmona, Loreto
    Raffeiner, Bernd
    Yardimci, Gozde Kubra
    Trefond, Ludovic
    Roux, Nicolas
    Rodrigues, Ana
    Papagoras, Charalampos
    Mateus, Elsa F.
    Mariette, Xavier
    Machado, Pedro M.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (01) : 145 - 150
  • [2] Vaccination against SARS-CoV-2 in patients with rheumatic diseases: doubts and perspectives
    Benucci, M.
    Infantino, M.
    Marotto, D.
    Ardizzone, S.
    Manfredi, M.
    Sarzi-Puttini, P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (01) : 196 - 202
  • [3] Seroprevalence of SARS-CoV-2 antibodies in patients with autoimmune inflammatory rheumatic diseases br
    Eviatar, T.
    Furer, V.
    Polachek, A.
    Levartovsky, D.
    Elalouf, O.
    Zisapel, M.
    Halperin, T.
    Turner, D.
    Paran, D.
    Pel, S.
    Nevo, S.
    Elkayam, O.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (07) : 1299 - 1305
  • [4] Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines
    Schulze-Koops, Hendrik
    Specker, Christof
    Skapenko, Alla
    RMD OPEN, 2021, 7 (01):
  • [5] SARS-CoV-2 vaccination willingness and humoral vaccination response in radiation oncology patients
    Geinitz, Hans
    Silberberger, Elisabeth
    Spiegl, Kurt
    Feichtinger, Johann
    Wagner, Helga
    Hermann, Philipp
    Braeutigam, Elisabeth
    Track, Christine
    Weis, Eva Maria
    Venhoda, Clemens
    Huppert, Roswitha
    Spindelbalker-Renner, Barbara
    Zauner-Babor, Georgine
    Nyiri, Dalma Viktoria
    Karasek, Nicola
    Erdei, Mercedesz
    Gheju, Ruben
    Gruber, Georg
    Egger, Margot
    Dieplinger, Benjamin
    VACCINE, 2024, 42 (04) : 945 - 959
  • [6] Humoral and cellular immunity in patients with rare autoimmune rheumatic diseases following SARS-CoV-2 vaccination
    Gumber, Leher
    Gomez, Nancy
    Hopkins, Georgina
    Tucis, Davis
    Bartlett, Laura
    Ayling, Kieran
    Vedhara, Kavita
    Steers, Graham
    Chakravorty, Mithun
    Rutter, Megan
    Jackson, Hannah
    Tighe, Patrick
    Ferraro, Alastair
    Power, Sheila
    Pradere, Marie-Josephe
    Onion, David
    Lanyon, Peter C.
    Pearce, Fiona A.
    Fairclough, Lucy
    RHEUMATOLOGY, 2023, 62 (06) : 2294 - 2303
  • [7] Outcomes following SARS-CoV-2 infection in individuals with and without inflammatory rheumatic diseases: a Danish nationwide cohort study
    Svensson, Annemarie Lyng Lyng
    Emborg, Hanne-Dorthe
    Bartels, Lars Erik
    Ellingsen, Torkell
    Adelsten, Thomas
    Cordtz, Rene
    Dreyer, Lene
    Obel, Niels
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (10) : 1359 - 1367
  • [8] RISK OF RELAPSE AFTER SARS-COV-2 VACCINATION IN PATIENTS WITH CHRONIC INFLAMMATORY NEUROPATHIES AND SAFETY AND TOLERABILITY OF THE SARS-COV-2 VACCINES
    Doneddu, Pietro
    Cocito, Dario
    Briani, Chiara
    Manganelli, Fiore
    Fabrizi, Gian Maria
    Mata, Sabrina
    Luigetti, Marco
    Inghilleri, Maurizio
    Carpo, Marinella
    Mazzeo, Anna
    Fazio, Raffaella
    Siciliano, Gabriele
    Filosto, Massimiliano
    Cosentino, Giuseppe
    Notturno, Francesca
    Sotgiu, Stefano
    Ruiu, Elena
    Antonini, Giovanni
    Giordano, Andrea
    Peci, Erdita
    Campagnolo, Marta
    Spina, Emanuele
    Cavallaro, Tiziana
    Sperti, Martina
    Romozzi, Marina
    Ceccanti, Marco
    Gentile, Luca
    Tronci, Stefano
    Schirinzi, Erika
    Piccinelli, Stefano Cotti
    Tamman, Giulia
    Carta, Alessandra
    Zarbo, Roberto
    Orazio, Eduardo Nobile
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2022, 27 : S81 - S82
  • [9] SARS-CoV-2 & rheumatic disease Consequences of the SARS-CoV-2 pandemic for patients with inflammatory rheumatic diseases. A comparison of the recommendations for action of rheumatological societies and risk assessment of different antirheumatic treatments
    Leipe, J.
    Hoyer, B. F.
    Iking-Konert, C.
    Schulze-Koops, H.
    Specker, C.
    Krueger, K.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (07): : 686 - 691
  • [10] Risk factors for SARS-CoV-2 infection in patients with rheumatic diseases
    Snarska, Weronika
    Jurkowska, Zuzanna
    Bobrowska-Snarska, Danuta
    Brzosko, Marek
    Przepiera-Bedzak, Hanna
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2021, 131 (12):